Article Text

Download PDFPDF
E-084 Recascularization efficacy of the 3d revascularization device versus solitaire in small core ischemic infarcts
  1. Siddiqui1,
  2. D Frei2,
  3. A Yoo3,
  4. J Kirmani4,
  5. O Zaidat5,
  6. D Lopes6,
  7. A Turk7,
  8. D Heck8,
  9. B Mason9,
  10. D Haussen10,
  11. E Levy1,
  12. S Mehta4,
  13. M Lazzaro11,
  14. M Chen6,
  15. A Dörfler12,
  16. C Derdeyn13,
  17. L Schwamm14,
  18. D Langer15,
  19. R Nogueira10
  1. 1SUNY University at Buffalo, Buffalo, NY
  2. 2Swedish Medical Center, Englewood, CO
  3. 3Texas Stroke Institute, Plano, TX
  4. 4John F. Kennedy Medical Center, Edison, NJ
  5. 5St. Vincent Mercy Medical Center, Toledo, OH
  6. 6Rush University Medical Center, Chicago, IL
  7. 7Medical University of South Carolina, Charleston, SC
  8. 8Forsyth Medical Center, Winston-Salem, NC
  9. 9Physicians Regional Medical Group, Naples, FL
  10. 10Grady Health System, Atlanta, GA
  11. 11Froetert Hospital, Milwaukee, WI
  12. 12Universitätsklinikum Erlangen, Erlanger, GERMANY
  13. 13University of Iowa, Iowa City, IA
  14. 14Massachusetts General Hospital, Boston, MA
  15. 15Lenox Hill Hospital, New York, NY.


Introduction Various thrombectomy devices promise high rates of recanalization and reduction of disability. A recent meta-analysis of the Solitaire device demonstrated its utility as safe and effective in revascularization of large vessel occlusions. The present analysis seeks to determine if good clinical outcome can similarly be achieved by the 3D Revascularization Device for patients with small score infarcts (ASPECTS 8-10).

Methods The 3D trial sought to evaluate the safety and efficacy of the 3D Revascularization Device as compared to the Penumbra System alone in acute stroke intervention. Subjects meeting the per protocol study criteria and presenting with small core infarcts were included in the present analysis. Notwithstanding similarities in baseline characteristics between the 3D ASPECTS 8–10 patients compared to the Campbell cohort (Table I), only patients with small core infarcts were considered for the present analysis. Study outcome on the reduction of disability, defined as mRS 0-2 at 90 days, were compared with the Campbell Solitaire meta-analysis.

Results In total, 105 of 198 patients met the study criteria. While ASPECTS 8-10 data could not be determined for the Campbell cohort, the median NIHSS (3D: 17 [IQR 12–21] vs Campbell: 17 [IQR 13–20] and ASPECTS (3D: 9 [IQR 8–10] vs 9 [IQR 7–10] scores were similar. Reduction of disability (mRS 0-2) data for available trials within the Campbell meta-analysis was extrapolated to evaluated to yield a weighted outcome of 57.7% at 90 days for ASPECTS 8–10 patients treated with the Solitaire device (Table II). Similarly, patients treated with the 3D Revascularization Device demonstrated comparable clinical outcomes, mRS 0–2 in 52.5% (figure 1).

Conclusion Utility of the 3D Revascularization Device with the Penumbra System can achieve favorable long term clinical outcome similar to the use of Solitaire.

Abstract E-0084 Table 1 Baseline characteristics of the 3D Trial Patients and Campbell Solitaire Meta-analysis

Abstract E-0084 Table 2 mRS 0-2 in Solitaire ASPECTS 8-10 patients

Abstract E-084 Figure 1

Functional independence in Small Core Patients (ASPECTS 8-10)

Disclosures: A. Siddiqui: 2; C; Codman, Medtronic, Guide Point Global Consulting, Penumbra, Stryker, Microvention, W. L. Gore & Associates, Three Rivers Medical, Inc., Corindus, Inc., Amnis Therapeutics, Ltd.,CereVasc, LLC. D. Frei: 2; C; Penumbra, Inc., Codman, Microvention, Stryker, Siemens. 4; C; Penumbra, Inc. A. Yoo: 1; C; Neuravi, Inc., Penumbra, Inc.. J. Kirmani: None. O. Zaidat: 2; C; Penumbra, Inc.. D. Lopes: None. A. Turk: 1; C; Penumbra, Inc., Microvention, Stryker, Covidien, Medina Medical. D. Heck: 1; C; Penumbra, Inc.. 2; C; Stryker. B. Mason: None. D. Haussen: None. E. Levy: None. S. Mehta: None. M. Lazzaro: None. M. Chen: None. A. Dörfler: 1; C; Penumbra, Inc.. C. Derdeyn: None. L. Schwamm: None. D. Langer: None. R. Nogueira: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.